Company: GIFLF
Filing Date: 2025-11-04
Form Type: 6-K
Source: 0001104659-25-106104
Chunk: 2

Company: Grifols SA
Filing Date: 2025-11-04
Form: 6-K
Chunk 2
---
PEX) - Others - Interest - Taxes. In the Consolidated Annual Accounts, 
 this reconciles to Cash flow generation from operating and inve sting activities excluding    
 impact from M&A and associated costs and expenses. Excludes lease payments, consistent        
 with prior disclosed guidance.                                                                |

| 3 | Guidance                                                                                     
 FX rate refers to FX rates as at 27 Feb 2025, consistent with page 38 of the Capital Markets 
 Day (CMD) presentation (EUR USD @ 1.04).                                                     |

Page 1 of 4

Nacho Abia, CEO of Grifols, said: "Grifols maintains momentum as we deliver on our Value Creation Plan. We are delivering clear progress across our key priorities, underpinned by underlying demand and stable market dynamics. The company remains well-positioned to navigate market conditions and deliver sustainable long-term value for all stakeholders."

Rahul Srinivasan, CFO of Grifols, added: "We are making tangible progress on free cashflow generation, which has required a coordinated and disciplined effort by the Grifols team across the entire organisation. Taking that same organisational focus and intensity forward remains a key priority.”

Revenue Performance Led by Biopharma

Biopharma delivered a 9.1% cc increase in revenue in the first nine months of the year, supported by 10.9% cc growth in the third quarter. The immunoglobulin (IG) franchise remained the key growth driver, with revenues up 14.4% cc year-to-date, reinforcing its position as the standard of care in primary and secondary immunodeficiencies as well as CIDP (Chronic inflammatory demyelinating polyneuropathy). The subcutaneous formulation continued its trajectory, rising more than 60% cc year- to-date.

Albumin performance was offset by pricing adjustments in China, resulting in a 3.9% cc year-to-date decline. The company continues to leverage its strategic local partnership to actively manage pricing dynamics and maintain a strong local market presence.

Alpha-1 and Specialty proteins franchises demonstrated solid progress, reaffirming Grifols’ market leadership in Alpha-1 and HyperRAB.

Diagnostic business maintains stable performance

The Diagnostic business unit generated EUR 479 million in revenue during the first nine months of the year, an increase of 1.4% cc, primarily driven by Blood Typing Solutions in the U.S. and Europe, and supported by Molecular Donor Screening in key countries. Noteworthy is the FDA